Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Multiple Myeloma
100%
Melphalan
100%
Platelet Engraftment
27%
Hospital Readmission
18%
Overall Survival
18%
Neutrophil Engraftment
18%
High Dose
9%
Dosing Schedule
9%
Engraftment
9%
Optimal Timing
9%
Transplant Outcomes
9%
Odds Ratio
9%
Transplantation Conditioning
9%
Conditioning Regimen
9%
Multivariable Model
9%
Performance Status
9%
Progression-free Survival
9%
Absolute Neutrophil Count
9%
High-risk Cytogenetics
9%
Split Dose
9%
Single-center Retrospective Study
9%
Medicine and Dentistry
Multiple Myeloma
100%
Stem Cell Transplant
100%
Melphalan
100%
Transplantation
36%
Engraftment
36%
Platelet
27%
Neutrophil
18%
Conditioning
18%
Overall Survival
18%
Drug Megadose
9%
Retrospective Study
9%
Progression Free Survival
9%
Absolute Neutrophil Count
9%
Odds Ratio
9%
Biochemistry, Genetics and Molecular Biology
Stem Cell Transplant
100%
Melphalan
100%
Platelet
27%
Overall Survival
18%
Conditioning
18%
Retrospective Study
9%
Cytogenetics
9%
Drug Megadose
9%
Progression Free Survival
9%
Absolute Neutrophil Count
9%
Pharmacology, Toxicology and Pharmaceutical Science
Melphalan
100%
Multiple Myeloma
100%
Overall Survival
18%
Retrospective Study
9%
Progression Free Survival
9%